thumbnail image

華潤三九藥業 (香港)有限公司

  • 關於我們
  • 產品介紹
  • 最新消息
  • 聯絡我們
  • …  
    • 關於我們
    • 產品介紹
    • 最新消息
    • 聯絡我們

華潤三九藥業 (香港)有限公司

  • 關於我們
  • 產品介紹
  • 最新消息
  • 聯絡我們
  • …  
    • 關於我們
    • 產品介紹
    • 最新消息
    • 聯絡我們
  • 我們的醫藥產品系列

    致力於提升您和家人的健康

  • 中藥產品

    傳承中醫智慧,帶來健康選擇

    - Dr. Li "China Resources Sanjiu's product quality is outstanding, especially in the field of cold medicine, my patients' feedback is very good." Our products have received the trust and support of over 500 medical institutions. China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large-scale state-owned listed pharmaceutical company focusing on the research, development, production, and sales of pharmaceutical products and related health services. Since its listing, the company has repeatedly won the honors of "Top 100 Golden Bulls" and "Top 100 Valued Companies" among listed companies on the main board of China. To date, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 Index, and FTSE Russell Index. The predecessor of China Resources Sanjiu was Shenzhen Nanfang Pharmaceutical Factory, established in 1985. In 1999, it was jointly established as a joint-stock company by five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd.; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code: 000999); in 2008, it officially became part of China Resources Group; in 2010, the company name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd." China Resources Sanjiu's core business focuses on CHC health consumer products and prescription drugs, with a diverse and continuously expanding product line. CHC's health consumer products primarily cover multiple categories including colds, digestive system, skin, hepatobiliary, pediatrics, orthopedics, gynecology, and cardiovascular diseases, with its core products holding a significant market share. Prescription drugs cover therapeutic areas such as cardiovascular, anti-tumor, and digestive system diseases, boasting several highly reputable medical products such as the Xue Sai Tong Sanqi series and Shen Fu injection. The company is committed to developing "original" 999 traditional Chinese medicine formula granules and "Sanjiu Bencao Wu" traditional Chinese medicine decoction pieces. The "999" brand enjoys high recognition among consumers and the pharmaceutical industry. Based on the "999" main brand, CR Sanjiu has established a "1+N" brand matrix spanning the entire product lifecycle. For many years, CR Sanjiu has consistently ranked among the top companies in the comprehensive rankings released by the China Nonprescription Medicines Association. Its 999 Cold Relief Granules/Capsules have continuously won first place in the cold and cough category (traditional Chinese medicine). Furthermore, many other CR Sanjiu products also rank highly. Facing the ever-changing pharmaceutical industry environment, China Resources Sanjiu actively seizes development opportunities in the industry and market, driving "high-quality development" through innovation. Adhering to a dual-engine approach of "brand + innovation," the company focuses on the innovative R&D and intelligent manufacturing of high-quality pharmaceutical and health products, optimizes its business structure, strengthens brand and channel construction, increases investment in innovation, explores innovative development models for the entire industrial chain, forms a competitive advantage across the entire traditional Chinese medicine industry chain, improves operational quality and efficiency, and achieves steady improvement in operating performance and core capabilities. In 2024, the company's operating revenue reached RMB 27.617 billion, a year-on-year increase of 11.63%; total profit was RMB 4.594 billion, a year-on-year increase of 22.35%; net profit attributable to shareholders of the listed company was RMB 3.368 billion, a year-on-year increase of 18.05%; and net profit after deducting non-recurring gains and losses was RMB 3.118 billion, a year-on-year increase of 15.01%. China Resources Sanjiu has always attached great importance to R&D and innovation, focusing on products such as "Shenfu Injection," "Honghua Injection," "Xintailin," and "999 Lixu Wangpai Xuesaitong Sanqi Soft Capsules." Its research projects have won the second prize of the National Science and Technology Progress Award.

    999單味中藥配方顆粒

    華潤三九專注於傳承與創新中醫藥核心理念,發掘和發揚中醫藥價值,緻力於打造“原質原味”的999中藥配方顆粒,開展全産業鏈價值管理,打造升級版傳統中醫藥解決方案,構建中醫藥綜合服務平台,成爲行業領先的中醫藥價值創造者。999單味中藥配方顆粒以其純正的藥性為依據,根據傳統中醫的理論,精選道地藥材,採用古法製作,使用經過淨化的水作為溶劑,並以傳統湯劑為基礎建立“標準煎劑”。通過標準煎劑的指紋圖譜,全面監控工藝過程(如提取、濃縮、乾燥、制粒與包裝),以確保物質的質量與臨床療效與傳統湯劑的一致性。999中藥配方顆粒自源頭把關,掌握核心藥材,擁有“國家基本藥物所需中藥材種子種苗繁育基地”及“嶺南中藥材種子種苗繁育基地”,構建完整可追溯的產業鏈,深入研究道地藥材資源及其質量評價,有效確保道地藥材的優質。

    劑量精準:

    每袋顆粒劑量標準化,避免傳統煎煮因火候、時間等導致藥效不均。
    醫生可根據病情精確配伍

    服用方便:

    顆粒劑型可直接用溫水沖服,無需傳統煎煮,節省時間,適合現代快節奏生活。

    攜帶方便:

    袋裝設計適合出國、旅行等場景。

    衛生安全:

    生產過程經過嚴格的品質控制,減少傳統中藥煎煮可能帶來的污染風險。

    密封包裝,延長保質期,減少變質風險

    多個品種供應,滿足用藥需求

    ~歡迎中醫診所/中醫師查詢~

    下載:999 單味中藥配方顆粒目錄

    - Director Chen As a member of the pharmaceutical industry, China Resources Sanjiu's innovative research and development has brought us new hope. Our products have received the trust and support of over 500 medical institutions. China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large-scale state-owned listed pharmaceutical company focusing on the research, development, production, and sales of pharmaceutical products and related health services. Since its listing, the company has repeatedly won the honors of "Top 100 Golden Bulls" and "Top 100 Valued Companies" among listed companies on the main board of China. To date, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 Index, and FTSE Russell Index. The predecessor of China Resources Sanjiu was Shenzhen Nanfang Pharmaceutical Factory, established in 1985. In 1999, it was jointly established as a joint-stock company by five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd.; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code: 000999); in 2008, it officially became part of China Resources Group; in 2010, the company name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd." China Resources Sanjiu's core business focuses on CHC health consumer products and prescription drugs, with a diverse and continuously expanding product line. CHC's health consumer products primarily cover multiple categories including colds, digestive system, skin, hepatobiliary, pediatrics, orthopedics, gynecology, and cardiovascular diseases, with its core products holding a significant market share. Prescription drugs cover therapeutic areas such as cardiovascular, anti-tumor, and digestive system diseases, boasting several highly reputable medical products such as the Xue Sai Tong Sanqi series and Shen Fu injection. The company is committed to developing "original" 999 traditional Chinese medicine formula granules and "Sanjiu Bencao Wu" traditional Chinese medicine decoction pieces. The "999" brand enjoys high recognition among consumers and the pharmaceutical industry. Based on the "999" main brand, CR Sanjiu has established a "1+N" brand matrix spanning the entire product lifecycle. For many years, CR Sanjiu has consistently ranked among the top companies in the comprehensive rankings released by the China Nonprescription Medicines Association. Its 999 Cold Relief Granules/Capsules have continuously won first place in the cold and cough category (traditional Chinese medicine). Furthermore, many other CR Sanjiu products also rank highly. Facing the ever-changing pharmaceutical industry environment, China Resources Sanjiu actively seizes development opportunities in the industry and market, driving "high-quality development" through innovation. Adhering to a dual-engine approach of "brand + innovation," the company focuses on the innovative R&D and intelligent manufacturing of high-quality pharmaceutical and health products, optimizes its business structure, strengthens brand and channel construction, increases investment in innovation, explores innovative development models for the entire industrial chain, forms a competitive advantage across the entire traditional Chinese medicine industry chain, improves operational quality and efficiency, and achieves steady improvement in operating performance and core capabilities. In 2024, the company's operating revenue reached RMB 27.617 billion, a year-on-year increase of 11.63%; total profit was RMB 4.594 billion, a year-on-year increase of 22.35%; net profit attributable to shareholders of the listed company was RMB 3.368 billion, a year-on-year increase of 18.05%; and net profit after deducting non-recurring gains and losses was RMB 3.118 billion, a year-on-year increase of 15.01%. China Resources Sanjiu has always attached great importance to R&D and innovation, focusing on products such as "Shenfu Injection," "Honghua Injection," "Xintailin," and "999 Lixu Wangpai Xuesaitong Sanqi Soft Capsules." Its research projects have won the second prize of the National Science and Technology Progress Award.

    華潤三九靈芝孢子油膠囊

    取自長白山的稀有靈芝,經由先進科技精華萃取,確保品質卓越,為您帶來無與倫比的健康體驗!嚴選長白山的煅木靈芝:破壁孢子粉,吸收效果卓越。採用CO2超臨界萃取技術:靈芝三萜的含量提升至99倍,效果更加明顯。符合GMP標準:在10萬級潔淨生產環境下,智能化生產,品質有保障。

    多重要認證:ISO9001、HACCP、CNAS,安全且可靠。

    (符合香港衛生署對農藥殘留、重金屬及微生物的相關標準)

    適合人群及服用方法

    長期從事腦力勞動或處於高度工作壓力狀態的人如都市白領,服用1~2週後可明顯改善疲倦乏力、注意力下降、煩躁失眠等症狀。長期服用可增強身體抵抗力。

    推薦:

    30~50歲 :每天1粒,空腹溫開水服用。

    50~65歲 :每天2粒,空腹溫開水服用。

    65歲以上:每天3粒,空腹溫開水服用。

    (失眠者建議睡前服用)

    慢性病患者如高血壓、高血脂、高血糖、肝功能異常者,服用30天後可減輕症狀。
    推薦:

    每天2次,每次2粒,飯後溫開水服用。或在中醫師指導下服用。

    特殊人群如腫瘤患者等,請在中醫師指導下服用。

    規 格:400mg x 30粒/樽

    保質期:24個月

    建議零售價:HKD $999


    儲存方法:室溫乾燥處,避免陽光直射

    - Mr. Zheng I really like China Resources Sanjiu's traditional Chinese medicine products, their effects are significant and side effects are few. Our products have received the trust and support of over 500 medical institutions. China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large-scale state-owned listed pharmaceutical company focusing on the research, development, production, and sales of pharmaceutical products and related health services. Since its listing, the company has repeatedly won the honors of "Top 100 Golden Bulls" and "Top 100 Valued Companies" among listed companies on the main board of China. To date, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 Index, and FTSE Russell Index. The predecessor of China Resources Sanjiu was Shenzhen Nanfang Pharmaceutical Factory, established in 1985. In 1999, it was jointly established as a joint-stock company by five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd.; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code: 000999); in 2008, it officially became part of China Resources Group; in 2010, the company name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd." China Resources Sanjiu's core business focuses on CHC health consumer products and prescription drugs, with a diverse and continuously expanding product line. CHC's health consumer products primarily cover multiple categories including colds, digestive system, skin, hepatobiliary, pediatrics, orthopedics, gynecology, and cardiovascular diseases, with its core products holding a significant market share. Prescription drugs cover therapeutic areas such as cardiovascular, anti-tumor, and digestive system diseases, boasting several highly reputable medical products such as the Xue Sai Tong Sanqi series and Shen Fu injection. The company is committed to developing "original" 999 traditional Chinese medicine formula granules and "Sanjiu Bencao Wu" traditional Chinese medicine decoction pieces. The "999" brand enjoys high recognition among consumers and the pharmaceutical industry. Based on the "999" main brand, CR Sanjiu has established a "1+N" brand matrix spanning the entire product lifecycle. For many years, CR Sanjiu has consistently ranked among the top companies in the comprehensive rankings released by the China Nonprescription Medicines Association. Its 999 Cold Relief Granules/Capsules have continuously won first place in the cold and cough category (traditional Chinese medicine). Furthermore, many other CR Sanjiu products also rank highly. Facing the ever-changing pharmaceutical industry environment, China Resources Sanjiu actively seizes development opportunities in the industry and market, driving "high-quality development" through innovation. Adhering to a dual-engine approach of "brand + innovation," the company focuses on the innovative R&D and intelligent manufacturing of high-quality pharmaceutical and health products, optimizes its business structure, strengthens brand and channel construction, increases investment in innovation, explores innovative development models for the entire industrial chain, forms a competitive advantage across the entire traditional Chinese medicine industry chain, improves operational quality and efficiency, and achieves steady improvement in operating performance and core capabilities. In 2024, the company's operating revenue reached RMB 27.617 billion, a year-on-year increase of 11.63%; total profit was RMB 4.594 billion, a year-on-year increase of 22.35%; net profit attributable to shareholders of the listed company was RMB 3.368 billion, a year-on-year increase of 18.05%; and net profit after deducting non-recurring gains and losses was RMB 3.118 billion, a year-on-year increase of 15.01%. China Resources Sanjiu has always attached great importance to R&D and innovation, focusing on products such as "Shenfu Injection," "Honghua Injection," "Xintailin," and "999 Lixu Wangpai Xuesaitong Sanqi Soft Capsules." Its research projects have won the second prize of the National Science and Technology Progress Award.

    JabaraX 百樂補

    Jabara,指原產於日本和歌山縣的無核柑橘。與普通柚子與青檸相比,富含更多「柚皮苷」,具有獨特的甜味和酸味。「柚皮苷」廣泛存在於 Jabara 的果實及果皮中,是一種具有強效抗過敏和抗炎症作用的類黃酮物質,對緩解花粉症、改善皮膚過敏及炎症等方面有一定功效(黃酮類屬於「多酚類」的一種)。JabaraX 百樂補,由日本大阪藥科大學研究開發,並在日本通過 GMP 認證工廠生產的高端健康輔助食品。由華潤三九藥業(香港)有限公司引入。(華潤集團旗下的大型國有製藥企業。)JabaraX 百樂補,使用經嚴格甄選的 Jabara 果實,加以專利技術製成的果皮粉末 JabaraX,並透過特殊工藝制成水溶性粉末。其有效成份含量約為普通柑橘類原料的 100 倍。

    適用人群:

    • 受 PM2.5 或沙塵影響困擾的人群
    • 患有i花粉過敏症者
    • 對室內灰塵過敏者
    • 有皮膚過敏困擾者
    • 需要緩解炎症者
    • 加強免疫功能者

    服用方法:

    成人:每日 1~2 包,撕開倒入口中,用水送服

    較嚴重敏感體質者:每日 2 包,連續服用 30 天


    兒童:每日 1 包,可用溫水溶解後服用,或在營養師指導下服用


    規 格:15包/盒

    保質期:36 個月

    建議零售價:HKD $


    儲存方法:室溫乾燥處,避免陽光直射

    - Mr. Zheng I really like China Resources Sanjiu's traditional Chinese medicine products, their effects are significant and side effects are few. Our products have received the trust and support of over 500 medical institutions. China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large-scale state-owned listed pharmaceutical company focusing on the research, development, production, and sales of pharmaceutical products and related health services. Since its listing, the company has repeatedly won the honors of "Top 100 Golden Bulls" and "Top 100 Valued Companies" among listed companies on the main board of China. To date, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 Index, and FTSE Russell Index. The predecessor of China Resources Sanjiu was Shenzhen Nanfang Pharmaceutical Factory, established in 1985. In 1999, it was jointly established as a joint-stock company by five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd.; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code: 000999); in 2008, it officially became part of China Resources Group; in 2010, the company name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd." China Resources Sanjiu's core business focuses on CHC health consumer products and prescription drugs, with a diverse and continuously expanding product line. CHC's health consumer products primarily cover multiple categories including colds, digestive system, skin, hepatobiliary, pediatrics, orthopedics, gynecology, and cardiovascular diseases, with its core products holding a significant market share. Prescription drugs cover therapeutic areas such as cardiovascular, anti-tumor, and digestive system diseases, boasting several highly reputable medical products such as the Xue Sai Tong Sanqi series and Shen Fu injection. The company is committed to developing "original" 999 traditional Chinese medicine formula granules and "Sanjiu Bencao Wu" traditional Chinese medicine decoction pieces. The "999" brand enjoys high recognition among consumers and the pharmaceutical industry. Based on the "999" main brand, CR Sanjiu has established a "1+N" brand matrix spanning the entire product lifecycle. For many years, CR Sanjiu has consistently ranked among the top companies in the comprehensive rankings released by the China Nonprescription Medicines Association. Its 999 Cold Relief Granules/Capsules have continuously won first place in the cold and cough category (traditional Chinese medicine). Furthermore, many other CR Sanjiu products also rank highly. Facing the ever-changing pharmaceutical industry environment, China Resources Sanjiu actively seizes development opportunities in the industry and market, driving "high-quality development" through innovation. Adhering to a dual-engine approach of "brand + innovation," the company focuses on the innovative R&D and intelligent manufacturing of high-quality pharmaceutical and health products, optimizes its business structure, strengthens brand and channel construction, increases investment in innovation, explores innovative development models for the entire industrial chain, forms a competitive advantage across the entire traditional Chinese medicine industry chain, improves operational quality and efficiency, and achieves steady improvement in operating performance and core capabilities. In 2024, the company's operating revenue reached RMB 27.617 billion, a year-on-year increase of 11.63%; total profit was RMB 4.594 billion, a year-on-year increase of 22.35%; net profit attributable to shareholders of the listed company was RMB 3.368 billion, a year-on-year increase of 18.05%; and net profit after deducting non-recurring gains and losses was RMB 3.118 billion, a year-on-year increase of 15.01%. China Resources Sanjiu has always attached great importance to R&D and innovation, focusing on products such as "Shenfu Injection," "Honghua Injection," "Xintailin," and "999 Lixu Wangpai Xuesaitong Sanqi Soft Capsules." Its research projects have won the second prize of the National Science and Technology Progress Award.

    ODM 東華三院「草本健康茶」系列

    本著天然草本養生的理念,東華三院推出三款自家品牌「草本健康茶」-益氣西洋參茶、明目杞菊茶及舒心玫瑰花茶,現時東華三院屬下各中醫科研中心及中醫診所均有代售。茶包採用優質天然草本調配而成,不含任何添加成份,清新可口,沖泡方便,為繁忙的都市人提供天然、便捷的養生保健方法。原材料全部經過嚴格鑑定,所有產品均通過SGS有機氯農藥、重金屬及微生物測試,以保證茶包質量安全。

    益氣西洋參茶★

    適合氣虛、容易疲倦和煩躁、思想不易集中及抽煙者飲用。成份:西洋參、三七花、龍眼肉及甘草。甘香可口,滋潤解渴,飲後帶給你心曠神怡的感覺,有助消除壓力,緩解疲勞。小提示:外感人士不宜飲用。


    明目杞菊茶★

    適合長時間使用電腦工作或閱讀、熬夜人士飲用。成份:枸杞子、菊花、龍眼肉及甘草。氣香味甘、清肝明目。飲後帶給你神清氣爽的感覺,有助紓緩眼睛疲勞、視力模糊。小提示:風寒外感人士不宜飲用。

    舒心玫瑰花茶★

    適合工作壓力大、消化不良及皮膚暗啞者飲用。成份:玫瑰花、紅棗、黨參及山楂。性質溫和,甘香可口,悠悠天然玫瑰花香令人身心舒暢,容光煥發,飲用能舒緩女性不適,山楂微酸有助消滯。小提示:外感、陰虛火旺人士不宜飲用。

Copyright © 華潤三九藥業(香港)有限公司

    主頁
    聯系我們
Cookie的使用
我們使用cookies來確保流暢的瀏覽體驗。若繼續,我們會認爲你接受使用cookies。
了解更多